Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab Soravtansine and Gemcitabine in FRa-positive Recurrent Cancers
NCT02996825Phase 1Completed
- Sponsor
- City of Hope
- Start
- Oct 2017
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mirvetuximab soravtansine in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC) and 2 more, sponsored by City of Hope. Primary endpoint: Recommended Phase II Dose at 3 weeks. Started Oct 2017; status: completed.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)endometrial cancer (EC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02996825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996825.